| Autor: |
Lohmueller JJ; University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA USA., Ham JD; University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA USA.; Carnegie Mellon University, Department of Biomedical Engineering, Pittsburgh, PA USA., Kvorjak M; University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA USA., Finn OJ; University of Pittsburgh School of Medicine, Department of Immunology, Pittsburgh, PA USA. |
| Abstrakt: |
Chimeric antigen receptor T cells (CAR-Ts) are promising cancer therapeutics. However, since cancer cells can lose the CAR-targeted antigen and avoid destruction, targeting multiple antigens with multiple CARs has been proposed. We illustrate here a less cumbersome alternative, anti-tag CARs (AT-CARs) that bind to tags on tumor-targeting antibodies. We have created novel AT-CARs, using the affinity-enhanced monomeric streptavidin 2 (mSA2) biotin-binding domain that when expressed on T cells can target cancer cells coated with biotinylated antibodies. Human T cells expressing mSA2 CARs with CD28-CD3ζ and 4-1BB-CD3ζ signaling domains were activated by plate-immobilized biotin and by tumor cells coated with biotinylated antibodies against the tumor-associated antigens CD19 and CD20. Furthermore, mSA2 CAR T cells were capable of mediating cancer cell lysis and IFNγ production in an antibody dose-dependent manner. The mSA2 CAR is a universal AT-CAR that can be combined with biotinylated tumor-specific antibodies to potentially target many different tumor types. |
